JCR Pharmaceuticals : Notice regarding Capital Expenditures to Increase Production Capacity at the Seishin Plant
07/31/2020 | 03:07am EDTNews Release
July31, 2020
JCR Pharmaceuticals Co., Ltd.
Translation
Notice regarding Capital Expenditures
to Increase Production Capacity at the Seishin Plant
JCR Pharmaceuticals Co., Ltd. (TSE 4552: Chairman and President Shin Ashida, "JCR") announced today about capital expenditures to expand the manufacturing area to increase production capacity for TEMCELL®HS Inj.
Seishin Plant, one of JCR's production bases, manufactures TEMCELL®HS Inj., a regenerative medical product, and medical devices. Medical institutions have highly rated TEMCELL®HS Inj. since its launch in 2016 and JCR has received orders far in excess of its initial forecasts.
JCR has addressed this increased demand by moving ahead with efforts to increase production, including boosted capital expenditures up until now, and has now decided to expand the Seishin Plant's manufacturing area to further expand its production capacity.
This expansion will raise the production capacity for TEMCELL®HS Inj. by about 30% over current levels, ensure an appropriate inventory and enable sufficient supply to meet the market's robust demand. The concept, specifications studies, contractor selection and other matters related to this expansion have already been completed.
Costs foreseen in this expansion are mainly expected to arise in the future and are expected to have only a negligible effect on JCR's consolidated financial results for the fiscal year ending March 31, 2021.
As a specialty pharma engaged in the development of pharmaceutical products for rare diseases, JCR will continue to strengthen business activities in the future and strive to contribute to the treatment of as many patients as possible.
- Overview of the Manufacturing Area Expansion Plan
Establish a new manufacturing area by expanding within the
Investment Details
Seishin Plant, increase the TEMCELL®HS Inj. production line
and enlarge storage space.
Total construction costs
Approximately 200 million yen
Start of operationsMay 2021 (scheduled)
https://www.marketscreener.com/JCR-PHARMACEUTICALS-CO--11551531/news/JCR-Pharmaceuticals-Notice-regarding-Capital-Expenditures-to-Increase-Production-Capacity-at-the-S-31028249/
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-5391
-
- There are more pages in this discussion • 12,639 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B |
Open | High | Low | Value | Volume |
98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 71720 | 94.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
94.5¢ | 10463 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 65720 | 0.940 |
3 | 31070 | 0.935 |
4 | 85753 | 0.930 |
2 | 9000 | 0.925 |
5 | 75776 | 0.920 |
Price($) | Vol. | No. |
---|---|---|
0.945 | 10463 | 1 |
0.950 | 50000 | 2 |
0.955 | 64000 | 1 |
0.960 | 30220 | 3 |
0.965 | 44050 | 3 |
Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |